High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle

Csanad G. Varallyay, Eric Nesbit, Rongwei (Rochelle) Fu, Seymur Gahramanov, Brendan Moloney, Eric Earl, Leslie Muldoon, Xin Li, William Rooney, Edward Neuwelt

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Cerebral blood volume (CBV) measurement complements conventional magnetic resonance imaging (MRI) to indicate pathologies in the central nervous system (CNS). Dynamic susceptibility contrast (DSC) perfusion imaging is limited by low resolution and distortion. Steady-state (SS) imaging may provide higher resolution CBV maps but was not previously possible in patients. We tested the feasibility of clinical SS-CBV measurement using ferumoxytol, a nanoparticle blood pool contrast agent. SS-CBV measurement was analyzed at various ferumoxytol doses and compared with DSC-CBV using gadoteridol. Ninety nine two-day MRI studies were acquired in 65 patients with CNS pathologies. The SS-CBV maps showed improved contrast to noise ratios, decreased motion artifacts at increasing ferumoxytol doses. Relative CBV (rCBV) values obtained in the thalamus and tumor regions indicated good consistency between the DSC and SS techniques when the higher dose (510 mg) ferumoxytol was used. The SS-CBV maps are feasible using ferumoxytol in a clinical dose of 510 mg, providing higher resolution images with comparable rCBV values to the DSC technique. Physiologic imaging using nanoparticles will be beneficial in visualizing CNS pathologies with high vascularity that may or may not correspond with blood-brain barrier abnormalities.

Original languageEnglish (US)
Pages (from-to)780-786
Number of pages7
JournalJournal of Cerebral Blood Flow and Metabolism
Volume33
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Ferrosoferric Oxide
Central Nervous System Neoplasms
Nanoparticles
Central Nervous System
Pathology
Magnetic Resonance Imaging
Perfusion Imaging
ferric oxide
Cerebral Blood Volume
Blood-Brain Barrier
Thalamus
Artifacts
Contrast Media
Noise

Keywords

  • dynamic MR
  • ferumoxytol
  • relative cerebral blood volume
  • steady state

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Neurology

Cite this

@article{3b1abf418bbf42a49265c9f36f2ebf3d,
title = "High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle",
abstract = "Cerebral blood volume (CBV) measurement complements conventional magnetic resonance imaging (MRI) to indicate pathologies in the central nervous system (CNS). Dynamic susceptibility contrast (DSC) perfusion imaging is limited by low resolution and distortion. Steady-state (SS) imaging may provide higher resolution CBV maps but was not previously possible in patients. We tested the feasibility of clinical SS-CBV measurement using ferumoxytol, a nanoparticle blood pool contrast agent. SS-CBV measurement was analyzed at various ferumoxytol doses and compared with DSC-CBV using gadoteridol. Ninety nine two-day MRI studies were acquired in 65 patients with CNS pathologies. The SS-CBV maps showed improved contrast to noise ratios, decreased motion artifacts at increasing ferumoxytol doses. Relative CBV (rCBV) values obtained in the thalamus and tumor regions indicated good consistency between the DSC and SS techniques when the higher dose (510 mg) ferumoxytol was used. The SS-CBV maps are feasible using ferumoxytol in a clinical dose of 510 mg, providing higher resolution images with comparable rCBV values to the DSC technique. Physiologic imaging using nanoparticles will be beneficial in visualizing CNS pathologies with high vascularity that may or may not correspond with blood-brain barrier abnormalities.",
keywords = "dynamic MR, ferumoxytol, relative cerebral blood volume, steady state",
author = "Varallyay, {Csanad G.} and Eric Nesbit and Fu, {Rongwei (Rochelle)} and Seymur Gahramanov and Brendan Moloney and Eric Earl and Leslie Muldoon and Xin Li and William Rooney and Edward Neuwelt",
year = "2013",
month = "5",
doi = "10.1038/jcbfm.2013.36",
language = "English (US)",
volume = "33",
pages = "780--786",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle

AU - Varallyay, Csanad G.

AU - Nesbit, Eric

AU - Fu, Rongwei (Rochelle)

AU - Gahramanov, Seymur

AU - Moloney, Brendan

AU - Earl, Eric

AU - Muldoon, Leslie

AU - Li, Xin

AU - Rooney, William

AU - Neuwelt, Edward

PY - 2013/5

Y1 - 2013/5

N2 - Cerebral blood volume (CBV) measurement complements conventional magnetic resonance imaging (MRI) to indicate pathologies in the central nervous system (CNS). Dynamic susceptibility contrast (DSC) perfusion imaging is limited by low resolution and distortion. Steady-state (SS) imaging may provide higher resolution CBV maps but was not previously possible in patients. We tested the feasibility of clinical SS-CBV measurement using ferumoxytol, a nanoparticle blood pool contrast agent. SS-CBV measurement was analyzed at various ferumoxytol doses and compared with DSC-CBV using gadoteridol. Ninety nine two-day MRI studies were acquired in 65 patients with CNS pathologies. The SS-CBV maps showed improved contrast to noise ratios, decreased motion artifacts at increasing ferumoxytol doses. Relative CBV (rCBV) values obtained in the thalamus and tumor regions indicated good consistency between the DSC and SS techniques when the higher dose (510 mg) ferumoxytol was used. The SS-CBV maps are feasible using ferumoxytol in a clinical dose of 510 mg, providing higher resolution images with comparable rCBV values to the DSC technique. Physiologic imaging using nanoparticles will be beneficial in visualizing CNS pathologies with high vascularity that may or may not correspond with blood-brain barrier abnormalities.

AB - Cerebral blood volume (CBV) measurement complements conventional magnetic resonance imaging (MRI) to indicate pathologies in the central nervous system (CNS). Dynamic susceptibility contrast (DSC) perfusion imaging is limited by low resolution and distortion. Steady-state (SS) imaging may provide higher resolution CBV maps but was not previously possible in patients. We tested the feasibility of clinical SS-CBV measurement using ferumoxytol, a nanoparticle blood pool contrast agent. SS-CBV measurement was analyzed at various ferumoxytol doses and compared with DSC-CBV using gadoteridol. Ninety nine two-day MRI studies were acquired in 65 patients with CNS pathologies. The SS-CBV maps showed improved contrast to noise ratios, decreased motion artifacts at increasing ferumoxytol doses. Relative CBV (rCBV) values obtained in the thalamus and tumor regions indicated good consistency between the DSC and SS techniques when the higher dose (510 mg) ferumoxytol was used. The SS-CBV maps are feasible using ferumoxytol in a clinical dose of 510 mg, providing higher resolution images with comparable rCBV values to the DSC technique. Physiologic imaging using nanoparticles will be beneficial in visualizing CNS pathologies with high vascularity that may or may not correspond with blood-brain barrier abnormalities.

KW - dynamic MR

KW - ferumoxytol

KW - relative cerebral blood volume

KW - steady state

UR - http://www.scopus.com/inward/record.url?scp=84877585941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877585941&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2013.36

DO - 10.1038/jcbfm.2013.36

M3 - Article

VL - 33

SP - 780

EP - 786

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 5

ER -